Literature DB >> 10395378

Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin.

T Hatziioannou1, E Delahaye, F Martin, S J Russell, F L Cosset.   

Abstract

We have previously shown that retroviral vector particles derived from Moloney murine leukemia virus (Mo-MuLV) can efficiently incorporate influenza hemagglutinin (HA) glycoproteins from fowl plague virus (FPV), thus conferring a broad tropism to the vectors. To modify its host range, we have engineered the FPV HA to display four different polypeptides on its N terminus: the epidermal growth factor, an anti-human MHC class I molecules scFv (single-chain antibody), an anti-melanoma antigen scFv, and an IgG Fc-binding polypeptide. All recombinant HA glycoproteins were correctly expressed and processed, and efficiently incorporated into Mo-MuLV retroviral particles, indicating that amino-terminal insertion of large polypeptides did not alter the conformation of HA chimeras. Virions carrying the different chimeras bound specifically to cells expressing the targeted cell surface molecules of each ligand. In addition, all virion types were infectious but exhibited various degrees of specificity regarding the use of the targeted cell surface molecule versus the wild-type FPV HA receptor for cell entry and infection. For some ligands tested, infectivity was significantly increased on cells that express the targeted receptor, compared with cells that express only the wild-type HA receptor. Furthermore, some polypeptides could abolish infectivity via the wild-type FPV HA receptor. Our data therefore indicate that it is possible to engineer the HA envelope glycoprotein by fusing ligands to its amino-terminal end without affecting its fusion activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395378     DOI: 10.1089/10430349950017860

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  19 in total

1.  Role of chimeric murine leukemia virus env beta-turn polyproline spacers in receptor cooperation.

Authors:  S Valsesia-Wittmann
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor.

Authors:  S Snitkovsky; T M Niederman; B S Carter; R C Mulligan; J A Young
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 3.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

4.  Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Authors:  William A Langley; Konrad C Bradley; Zhu-Nan Li; Mary Ellen Smith; Matthias J Schnell; David A Steinhauer
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

5.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

Review 6.  Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems.

Authors:  Sabine Boeckle; Ernst Wagner
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

Review 7.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

8.  Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity.

Authors:  Zhu-Nan Li; Scott N Mueller; Ling Ye; Zhigao Bu; Chinglai Yang; Rafi Ahmed; David A Steinhauer
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 9.  Lentiviral vectors in gene therapy: their current status and future potential.

Authors:  David Escors; Karine Breckpot
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-02-09       Impact factor: 4.291

10.  Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.

Authors:  Min-Chul Kim; Yu-Na Lee; Yu-Jin Kim; Hyo-Jick Choi; Ki-Hye Kim; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2017-10-26       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.